| Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587) |
|---|
| 03/23/2006 | US20060063775 4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazine-1-carboxylic acid benzhydryl-amide; conjugated to polyethylene glycol; analgesic, antidiabetic and anticarcinogenic agent, antidepressant, anxiolytic agent |
| 03/23/2006 | US20060063772 New compounds |
| 03/23/2006 | US20060063771 CCR5 antagonists useful for treating AIDS |
| 03/23/2006 | US20060063770 Nitrogenous heterocyclic compounds |
| 03/23/2006 | US20060063767 Phthalazinone derivatives |
| 03/23/2006 | US20060063760 Hydroxamic acids useful in the treatment of hyper-proliferative disorders |
| 03/23/2006 | US20060063759 e.g. 5-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-3H-benzooxazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia, Crohn's disease |
| 03/23/2006 | US20060063758 Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity |
| 03/23/2006 | US20060063756 Janus Kinase JAK2 and JAK3; 4-chloro-6-(3,5-dimethylpiperazin-1-yl)pyrimidine; chemotherapeutic, antiproliferative, antiinflammatory, immunomodulatory agent; allergies, asthma, autoimmune diseases, transplant rejection, rheumatoid arthritis, multiple sclerosis |
| 03/23/2006 | US20060063751 Novel fused heterocycles and uses thereof |
| 03/23/2006 | US20060063247 Increased thermostability, photostability, and water solubility |
| 03/23/2006 | US20060061265 Aromatic amine derivative and organic electroluminescent element employing the same |
| 03/23/2006 | CA2580409A1 Triazole derivative or salt thereof |
| 03/23/2006 | CA2580243A1 5-heterocyclyl pyrimidines |
| 03/23/2006 | CA2580033A1 Imidazole compound |
| 03/23/2006 | CA2579847A1 Bicyclic anilide spirolactam cgrp receptor antagonists |
| 03/23/2006 | CA2579143A1 Vanilloid receptor ligands and their use in treatments |
| 03/23/2006 | CA2577181A1 Heteroaroyl-substituted serine amides utilized as herbicides |
| 03/23/2006 | CA2568832A1 Indole derivatives as antiviral agents |
| 03/22/2006 | EP1636221A2 New azetidine compounds |
| 03/22/2006 | EP1636208A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 03/22/2006 | EP1636197A1 Novel 3-substituted-1,4-benzodiazepines |
| 03/22/2006 | EP1636192A1 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators |
| 03/22/2006 | EP1636181A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 03/22/2006 | EP1635837A1 (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| 03/22/2006 | EP1635835A1 2-aminopyrimidine derivatives as raf kinase inhibitors |
| 03/22/2006 | EP1635821A2 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl)amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
| 03/22/2006 | EP1635818A1 Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/22/2006 | EP1480951A4 Synthesis of indole thiazole compounds as ligands for the ah receptor |
| 03/22/2006 | EP1474417B1 Processes for preparing losartan and losartan potassium |
| 03/22/2006 | EP1472221B1 Substituted indoles, method for production and use thereof for the inhibition of pain |
| 03/22/2006 | EP1322635B1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 03/22/2006 | EP1309586B1 4-, 5-, 6- and 7-indole derivatives useful for the treatment of cns disorders |
| 03/22/2006 | EP1140924B1 Piperazine derivatives |
| 03/22/2006 | EP1029541B1 Therapeutic or prophylactic agent for glomerulopathy |
| 03/22/2006 | CN1751052A Therapeutic agents |
| 03/22/2006 | CN1751028A Non-nucleoside reverse transcriptase inhibitors |
| 03/22/2006 | CN1246318C Process for preparation of imidazole compounds |
| 03/22/2006 | CN1245979C Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as active ingredient |
| 03/22/2006 | CN1245978C Preventive or therapeutic drugs for various eosinophilia realated diseases containing chymase inhibitors as active ingredient |
| 03/21/2006 | US7015333 Process for preparation of imidazolyl compounds |
| 03/21/2006 | US7015241 Appetite-stimulating agents and remedies for anorexia |
| 03/21/2006 | US7015233 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
| 03/21/2006 | US7015229 An antagonist of a corticotropin releasing factor (CRF) receptor, treating central nervous system disorders or anxiety disorders, depression and stress |
| 03/21/2006 | US7015226 Hormone inhibitors such as 3-[2(R)-aminopropylamino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-methylsulfonylbenzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione, used as anticarcinogenic agents and for prophylaxis of glandular or urogenital disorders |
| 03/21/2006 | US7015220 enzyme inhibitors used as modulators of tyrosine kinase signal transduction and/or as antiproliferative agents; prophylaxis of vision defects, cancer, atherosclerosis, restenosis, metabolic disorders or autoimmune diseases |
| 03/21/2006 | US7015218 Amide compounds and medicinal use thereof |
| 03/21/2006 | US7015216 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| 03/21/2006 | CA2399358C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 03/21/2006 | CA2242416C Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| 03/21/2006 | CA2238816C N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists |
| 03/21/2006 | CA2193703C Protein kinase c inhibitors |
| 03/16/2006 | WO2006029057A1 Purification of olmesartan medoxomil |
| 03/16/2006 | WO2006029056A1 Preparation of olmesartan medoxomil |
| 03/16/2006 | WO2006028957A1 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 03/16/2006 | WO2006028904A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | WO2006028896A2 Chemical compounds |
| 03/16/2006 | WO2006027211A1 2,4-substituted pyrimidines as cysteine protease inhibitors |
| 03/16/2006 | WO2006027186A1 N-(1-(2,3-dihydro-1h-inden-5yl) -2-oxo-3-pyrrolidinyl) -sulfonamide derivatives for use as factor xa inhibitors |
| 03/16/2006 | WO2005121121A3 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 03/16/2006 | WO2005113535A3 Pyrazinylmethyl lactam derivatives |
| 03/16/2006 | WO2005077344A3 Hydantoin derivatives as inhibitors of cellular necrosis |
| 03/16/2006 | US20060058531 red pigments has superior dispersibility in binder, non-flocculated, produce a desired hue; contains p-benzenedicarboxylic acid group; printing inks, paints, colorants for various plastics, toner |
| 03/16/2006 | US20060058357 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke |
| 03/16/2006 | US20060058356 Indolylmaleimide derivatives |
| 03/16/2006 | US20060058351 Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof |
| 03/16/2006 | US20060058326 Pyrimidines, methods for the production thereof, and use thereof |
| 03/16/2006 | US20060058325 Therapeutic quniazoline derivatives |
| 03/16/2006 | US20060058318 Prodrugs of an ERK protein kinase inhibitor |
| 03/16/2006 | US20060058309 Respiratory syncytial virus replication inhibitors |
| 03/16/2006 | US20060058308 Vanilloid receptor ligands and their use in treatments |
| 03/16/2006 | US20060058305 Antiproliferative agents such as 3-(3-trifluoromethylphenyl)cinnolin-5-ol |
| 03/16/2006 | US20060058302 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases; example compound: 2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(2-ethyl-hexyl)-benzamide |
| 03/16/2006 | US20060058301 Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid |
| 03/16/2006 | US20060058298 Inhibitors of histone deacetylase |
| 03/16/2006 | US20060058292 2,4-pyrimidinediamine compounds and their uses |
| 03/16/2006 | US20060058289 Mercaptoimidazoles as ccr2 receptor antagonists |
| 03/16/2006 | US20060058285 Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
| 03/16/2006 | US20060058248 Processes for the preparation of 6-11 bicyclic erythromycin derivatives |
| 03/16/2006 | DE102004043826A1 Mixture of two metal azo complexes useful as a light absorber in the information layer of a write-once optical data carrier |
| 03/16/2006 | CA2578996A1 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 03/16/2006 | CA2578739A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | CA2575177A1 Purification of olmesartan medoxomil |
| 03/16/2006 | CA2573800A1 Preparation of olmesartan medoxomil |
| 03/15/2006 | EP1634880A2 Processes for preparing losartan and losartan potassium |
| 03/15/2006 | EP1634873A1 Sigma receptor inhibitors |
| 03/15/2006 | EP1633740A2 Chemical compounds |
| 03/15/2006 | EP1633739A1 Process for the preparation of anhydrous eleptritan hemisulphate |
| 03/15/2006 | EP1633738A2 Novel indole derivatives, method of preparing same in the form of medicaments, pharmaceutical compositions and, in particular, kdr inhibitors |
| 03/15/2006 | EP1633729A1 Sulphonamide compounds that modulate chemokine receptor activity (ccr4) |
| 03/15/2006 | EP1633728A1 2-substituted pyrimidines |
| 03/15/2006 | EP1633726A1 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 |
| 03/15/2006 | EP1633725A1 Hepatitis c virus inhibitors |
| 03/15/2006 | EP1633724A1 Phthalazinone derivatives |
| 03/15/2006 | EP1633710A1 Isoindolin-1-one compounds as kinase inhibitors |
| 03/15/2006 | EP1633349A1 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
| 03/15/2006 | EP1633348A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| 03/15/2006 | EP1633346A1 Pyrrolidin-1, 2- dicarboxylic acid- 1- (4- ethinyl- phenyl) - amid]- 2- (phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis |
| 03/15/2006 | EP1567151B1 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer |
| 03/15/2006 | EP1465864B1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |